Laboratorios Farmaceuticos Rovi, S.A. Share Price
Stocks
ROVI
ES0157261019
Pharmaceuticals
OTC Markets Traded|
Market Closed -
BME
16:35:15 23/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 59.25 EUR | +0.25% |
|
+2.42% | -6.69% |
| 07-23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| 07-23 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 3.03B 3.45B 2.85B 2.61B 4.86B 330B 4.9B 34.2B 13.26B 169B 12.95B 12.67B 546B | P/E 2026 * |
20x | P/E 2027 * | 17.6x |
|---|---|---|---|---|---|
| Enterprise Value | 3.02B 3.44B 2.84B 2.6B 4.85B 329B 4.89B 34.11B 13.22B 168B 12.91B 12.63B 545B | EV / Sales 2026 * |
3.9x | EV / Sales 2027 * | 3.31x |
| Free-Float |
31.63% | Yield 2026 * |
1.64% | Yield 2027 * | 1.96% |
| Markets | Quality | ||
|---|---|---|---|
BME
| ROVI | Delayed | |
CBOE
| ROVIe | Real-time | |
|
Tradegate
| 41L | Real-time | |
|
OTC Markets
| LABFF | Delayed | |
|
Berne S.E.
| 41L | End-of-day quote | |
|
Deutsche Boerse AG
| 41L | Delayed | |
|
CBOE
| 0ILL | Real-time | |
|
Börse Stuttgart
| 41L | Delayed | |
|
Boerse Muenchen
| 41L | Real-time | |
|
Wiener Boerse
| ROVI | End-of-day quote | |
|
Borsa Italiana
| 1ROVI | End-of-day quote |
Last Transcript: Laboratorios Farmaceuticos Rovi, S.A.
| 1 day | +0.25% | ||
| 1 week | +2.42% | ||
| Current month | -2.23% | ||
| 1 month | -0.92% | ||
| 3 months | +0.94% | ||
| 6 months | -24.43% | ||
| Current year | -6.69% |
| 1 week | 57.45 |  | 59.9 |
| 1 month | 56.95 | | 62.2 |
| Current year | 53.1 | | 86.7 |
| 1 year | 53.1 | | 86.7 |
| 3 years | 45.52 | | 94.8 |
| 5 years | 35.2 | | 94.8 |
| 10 years | 10.8 | | 94.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 26/07/2007 | |
| Director of Finance/CFO | - | 31/12/2000 | |
| Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 16/07/2021 | |
| Director/Board Member | - | 26/07/2007 | |
| Director/Board Member | - | 26/07/2007 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/06/23 | Buy | Director | 1,000 | 0.0019% | ||
| 13/04/22 | Norbel Inversiones SL
| Sell | Company | 560,690 | 1.0000% | |
| 15/03/22 | Norbel Inversiones SL
| Sell | Company | 2,803,448 | 5.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | +2.42% | +0.77% | +13.83% | 3.46B | |
| -1.64% | +1.31% | +52.46% | +109.07% | 1,043B | |
| -0.01% | +0.74% | +54.51% | +67.71% | 649B | |
| -0.05% | +0.78% | +19.09% | +73.55% | 469B | |
| -0.25% | +0.72% | +33.97% | +45.63% | 355B | |
| +0.98% | +3.30% | +19.63% | +27.91% | 270B | |
| -1.91% | +2.59% | +8.09% | +12.53% | 262B | |
| -1.01% | +8.10% | +41.99% | +51.70% | 222B | |
| -0.85% | +3.47% | +34.56% | +101.80% | 189B | |
| -2.53% | -8.57% | -34.17% | -60.67% | 175B | |
| Average | -0.41% | +2.19% | +23.09% | +44.30% | 363.65B | |
| Weighted average by Cap. | -0.05% | +2.19% | +35.30% | +65.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 774M 881M 727M 665M 1.24B 84.38B 1.25B 8.74B 3.39B 43.07B 3.31B 3.24B 140B | 892M 1.02B 838M 767M 1.43B 97.28B 1.44B 10.07B 3.91B 49.66B 3.81B 3.73B 161B |
| Net income | 146M 166M 137M 126M 235M 15.94B 237M 1.65B 640M 8.14B 625M 611M 26.36B | 173M 197M 162M 149M 278M 18.85B 280M 1.95B 757M 9.62B 739M 723M 31.16B |
| Net Debt | -8.5M -9.68M -7.98M -7.31M -13.64M -926M -13.74M -95.93M -37.2M -473M -36.33M -35.53M -1.53B | -72.51M -82.55M -68.09M -62.34M -116M -7.9B -117M -818M -317M -4.03B -310M -303M -13.07B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/09/26 | €59.25 | +0.25% | 80,397 |
| 22/09/26 | €59.10 | +0.42% | 87,377 |
| 21/09/26 | €58.85 | +2.08% | 80,702 |
| 18/09/26 | €57.65 | -1.71% | 98,680 |
| 17/09/26 | €58.65 | +0.69% | 64,260 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ROVI Stock
Select your edition
All financial news and data tailored to specific country editions
